Overview

Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Thirty-seven women aged 18-75 years with recurrent ovarian cancer were enrolled
Phase:
Phase 3
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University
Treatments:
Apatinib
Fluzoparib